Abuse-deterrent drug formulations
View Patent ↗An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
1. A therapeutically effective pharmaceutical composition comprising solid microparticles, wherein the microparticles comprise:
a. an active agent,
b. one or more fatty acids, and
c. one or more carrier materials selected from the group consisting of waxes or wax-like substances and mixtures thereof;
wherein the active agent comprises a fatty acid salt of oxycodone, and the one or more fatty acids are present in an amount ranging from 6.9 to 15 times the molar amount of active agent.
2. The composition of claim 1 , wherein the molar concentration of the one or more fatty acids in the microparticle is 6.9 to 10 times the molar amount of the active agent.
3. The composition of claim 1 , wherein the one or more fatty acids is one or more C 5 to C 30 monovalent fatty acids, one or more C 8 to C 40 divalent fatty acids, or mixtures thereof.
4. The composition of claim 2 , wherein the one or more fatty acids is one or more C 5 to C 30 monovalent fatty acids, one or more C 8 to C 40 divalent fatty acids, or mixtures thereof.
5. The composition of claim 3 , wherein the one or more fatty acids is one or more C 5 to C 30 monovalent fatty acids selected from the group consisting of pentanoic acid, hexanoic (caproic) acid, heptanoic acid, octanoic (caprylic) acid, nonanoic acid, decanoic (capric) acid, undecanoic acid, dodecanoic (lauric) acid, tridecanoic acid, tetradecanoic (myristic) acid, pentadecanoic acid, hexadecanoic (palmitic) acid, heptadecanoic (margaric) acid, octadecanoic (stearic) acid, nonadecanoic acid, eicosanoic (arachidic) acid, heneicosanoic acid, docosanoic (behenic) acid, tricosanoic acid, tetracosanoic (lignoceric) acid, pentacosanoic acid, hexacosanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid, linoleic acid, oleic acid, and mixtures thereof.
6. The composition of claim 4 , wherein the one or more fatty acids is one or more C 5 to C 30 monovalent fatty acids selected from the group consisting of pentanoic acid, hexanoic (caproic) acid, heptanoic acid, octanoic (caprylic) acid, nonanoic acid, decanoic (capric) acid, undecanoic acid, dodecanoic (lauric) acid, tridecanoic acid, tetradecanoic (myristic) acid, pentadecanoic acid, hexadecanoic (palmitic) acid, heptadecanoic (margaric) acid, octadecanoic (stearic) acid, nonadecanoic acid, eicosanoic (arachidic) acid, heneicosanoic acid, docosanoic (behenic) acid, tricosanoic acid, tetracosanoic (lignoceric) acid, pentacosanoic acid, hexacosanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid, linoleic acid, oleic acid, and mixtures thereof.
7. The composition of claim 5 , wherein the one or more fatty acids is myristic acid.
8. The composition of claim 6 , wherein the one or more fatty acids is myristic acid.
9. The composition of claim 1 , wherein the one or more carrier materials are present in an amount of from 0.25 to 8 times by weight of the amount of the active agent.
10. The composition of claim 2 , wherein the one or more carrier materials are present in an amount of from 0.25 to 8 times by weight of the amount of the active agent.
11. The composition of claim 9 , wherein the one or more carrier materials are present in an amount of from 2 to 6 times by weight of the amount of the active agent.
12. The composition of claim 10 , wherein the one or more carrier materials are present in an amount of from 2 to 6 times by weight of the amount of the active agent.
13. The composition of claim 1 , wherein the carrier material is a wax selected from the group consisting of carnauba wax, beeswax, microcrystalline wax and mixtures thereof.
14. The composition of claim 2 , wherein the carrier material is a wax selected from the group consisting of carnauba wax, beeswax, microcrystalline wax and mixtures thereof.
15. The composition of claim 13 , wherein the carrier material is a mixture of beeswax and carnauba wax.
16. The composition of claim 14 , wherein the carrier material is a mixture of beeswax and carnauba wax.
17. The composition of claim 1 , wherein the active agent comprises a myristic acid salt of oxycodone, the one or more fatty acids is myristic acid, and the carrier comprises beeswax and carnauba wax.
18. The composition of claim 2 , wherein the active agent comprises a myristic acid salt of oxycodone, the one or more fatty acids is myristic acid, and the carrier comprises beeswax and carnauba wax.
19. The composition of claim 1 , wherein the active agent is prepared by contacting a molar excess of the one or more fatty acids with the free base form of the drug.
20. The composition of claim 2 , wherein the active agent is prepared by contacting a molar excess of the one or more fatty acids with the free base form of the drug.
21. A pharmaceutical dosage form comprising the composition of claim 1 .
22. A pharmaceutical dosage form comprising the composition of claim 2 .
23. A pharmaceutical dosage form comprising the composition of claim 17 .
24. A pharmaceutical dosage form comprising the composition of claim 18 .
25. The pharmaceutical dosage form of claim 23 , in the form of a capsule.
26. The pharmaceutical dosage form of claim 24 , in the form of a capsule.